Healthy volunteers test new drug combo absorption
NCT ID NCT07133399
First seen Sep 30, 2025
Summary
This completed Phase 1 trial in 32 healthy adults compared how two different combinations of vicadrostat and empagliflozin are absorbed by the body. It also looked at whether food changes drug levels. Participants received a single dose of each combination in random order. The goal was to measure drug concentrations in the blood, not to treat any condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vicadrostat and empagliflozin combination
What this could lead to
If successful, this could help determine the best way to combine these two drugs for future studies.
What could go wrong
This is a very early, small study in healthy people, not patients. It only measures drug levels, not whether the drugs work for any disease.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.